PA-1 Xenograft Model Overview

The PA-1 xenograft model is derived from a human ovarian teratocarcinoma cell line, established from a patient with an aggressive form of ovarian cancer. This cell line is widely used in preclinical studies to investigate the biology of ovarian cancer, particularly the teratocarcinoma subtype, and to evaluate novel therapeutic strategies. Ovarian cancer is a leading cause of cancer-related deaths in women, and teratocarcinoma, being a rare and highly aggressive type of ovarian tumor, poses unique challenges in diagnosis and treatment. The PA-1 xenograft model is valuable for studying the tumor’s response to chemotherapy, targeted therapies, and for investigating mechanisms of drug resistance in ovarian cancer. Its high sensitivity to platinum-based chemotherapy agents, like cisplatin, makes it an excellent model for testing new agents and combination therapies aimed at overcoming resistance.

Request a Custom Quote for PA-1 Xenograft Model

Biological and Molecular Characteristics

PA-1 cells are characterized by their epithelial origin and express various markers associated with ovarian carcinoma, such as cytokeratins and epithelial membrane antigen (EMA). The PA-1 model also exhibits characteristics typical of teratocarcinoma, with the presence of differentiated tissues such as adipose, neural, and cartilage-like structures, making it unique among other ovarian cancer models. The cells are known to harbor mutations in key tumor suppressor genes such as TP53, which are implicated in resistance to apoptosis and contribute to aggressive tumor behavior. Additionally, PA-1 cells demonstrate high expression of drug resistance markers like MDR1 (multidrug resistance protein), which can limit the efficacy of chemotherapy treatments. This model is particularly useful for studying how these resistance mechanisms impact therapeutic responses and for evaluating novel drugs aimed at overcoming such resistance.

Marker	Expression Level	Function
Cytokeratin	High	Epithelial cell marker
EMA	High	Epithelial membrane antigen
TP53	Mutated	Tumor suppressor gene involved in apoptosis
MDR1	High	Multidrug resistance protein associated with chemotherapy resistance
CD44	High	Stem cell marker involved in tumor progression

In Vivo Model Development and Tumorigenicity

The PA-1 xenograft model is established by subcutaneously implanting PA-1 cells into immunocompromised mice, such as NOD/SCID or NSG mice, which lack functional T and B cells. Upon implantation, the cells form solid, rapidly growing tumors that resemble human ovarian teratocarcinomas in terms of histology and molecular characteristics. The tumors often exhibit a combination of solid and cystic growth, with areas of necrosis due to the rapid expansion of the tumor. PA-1 xenografts also display significant vascularization, which is indicative of active angiogenesis. The model is particularly useful for evaluating the effects of chemotherapy, as PA-1 cells are initially sensitive to platinum-based agents like cisplatin, but can develop resistance over time, making it a valuable tool for studying mechanisms of resistance and testing novel therapies.

The PA-1 model can also be developed through orthotopic implantation, where PA-1 cells are injected into the ovarian bursa of immunocompromised mice. This method closely mimics the natural site of tumor growth in the ovaries and allows for the study of tumor metastasis and peritoneal dissemination, which are key features of ovarian cancer progression.

Request a Custom Quote for PA-1 Xenograft Model

Histopathology and Immunohistochemical Profile

Histopathological analysis of PA-1 xenografts reveals the typical features of ovarian teratocarcinoma, with heterogeneous tumors containing multiple types of differentiated tissue, such as adipose, neural, and cartilage-like structures. The tumors show a combination of solid and cystic growth, often with areas of necrosis and high cellularity. Immunohistochemical staining of PA-1 xenografts reveals strong expression of epithelial markers, including cytokeratin and EMA, confirming the epithelial origin of the tumor. Additionally, PA-1 tumors show elevated levels of TP53, consistent with the presence of mutations in this tumor suppressor gene. Staining for MDR1 indicates the presence of multidrug resistance mechanisms, which may contribute to the tumor’s resistance to chemotherapy. The tumors also exhibit markers of angiogenesis, such as CD31, highlighting the high vascularization within the tumor, which supports its rapid growth.

Preclinical Applications and Drug Response

The PA-1 xenograft model is widely used to evaluate the efficacy of various therapeutic agents, particularly chemotherapy agents such as cisplatin and carboplatin, which are commonly used in ovarian cancer treatment. The model is particularly valuable for studying mechanisms of chemotherapy resistance, as PA-1 cells can develop resistance to platinum-based therapies, providing an ideal platform for testing new drugs aimed at overcoming this resistance. In addition to chemotherapy, the PA-1 xenograft model is useful for investigating targeted therapies, particularly those targeting the PI3K/AKT/mTOR and RAS/MAPK pathways, which are often dysregulated in ovarian cancer. Furthermore, the model is employed to evaluate novel agents aimed at modulating the tumor microenvironment, including anti-angiogenic therapies and immune checkpoint inhibitors.

The PA-1 xenograft model is also increasingly used for testing combination therapies, where chemotherapy agents are combined with targeted inhibitors or immunotherapies, to improve therapeutic outcomes in ovarian cancer. Given the model’s ability to replicate key aspects of ovarian teratocarcinoma, it is a valuable tool for preclinical research aimed at developing more effective treatments for this aggressive and challenging cancer subtype.

Request This Model

To request the PA-1 xenograft model for your preclinical studies, please use the form below. A customized quote and additional model specifications will be provided upon inquiry.

Request a Custom Quote for PA-1 Xenograft Model